FDA clears Click Therapeutics' Motivista, first digital therapeutic for negative schizophrenia symptoms

Click Therapeutics received FDA 510(k) clearance for its digital therapeutic, Motivista (formerly CT-155), marking the first authorized treatment targeting negative symptoms of schizophrenia in the United States.

The therapy is intended as an adjunct to clinician-managed antipsychotic medication for adults with stable positive symptoms, delivering goal-setting, cognitive restructuring, and social-skills training via a smartphone app.

By addressing social withdrawal, reduced pleasure, and diminished emotional expression-areas not well served by existing antipsychotics-Motivista aims to fill a significant unmet need in precision psychiatry.